Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial
The Fly

Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial

Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial of the company’s lead asset, EryDex, for the treatment of Ataxia-Telangiectasia (A-T).

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App